WallStSmart

Artivion Inc (AORT)vsNovartis AG ADR (NVS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 11804% more annual revenue ($57.36B vs $481.88M). NVS leads profitability with a 17.5% profit margin vs -3.6%. NVS appears more attractively valued with a PEG of 3.84. NVS earns a higher WallStSmart Score of 48/100 (D+).

AORT

Hold

35

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 3.0Quality: 6.5
Piotroski: 4/9Altman Z: 1.46

NVS

Hold

48

out of 100

Grade: D+

Growth: 4.0Profit: 9.0Value: 2.7Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AORTSignificantly Overvalued (-28.3%)

Margin of Safety

-28.3%

Fair Value

$31.25

Current Price

$19.40

$11.85 premium

UndervaluedFair: $31.25Overvalued
NVSSignificantly Overvalued (-69.8%)

Margin of Safety

-69.8%

Fair Value

$95.76

Current Price

$160.32

$64.56 premium

UndervaluedFair: $95.76Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AORT1 strengths · Avg: 8.0/10
Price/BookValuation
2.1x8/10

Reasonable price relative to book value

NVS4 strengths · Avg: 9.3/10
Market CapQuality
$303.67B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
34.3%10/10

Strong operational efficiency at 34.3%

Return on EquityProfitability
26.9%9/10

Every $100 of equity generates 27 in profit

Free Cash FlowQuality
$4.76B8/10

Generating 4.8B in free cash flow

Areas to Watch

AORT4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$998.73M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
4.9%3/10

Operating margin of 4.9%

PEG RatioValuation
181.502/10

Expensive relative to growth rate

NVS4 concerns · Avg: 4.0/10
P/E RatioValuation
30.7x4/10

Premium valuation, high expectations priced in

Price/BookValuation
8.1x4/10

Trading at 8.1x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AORT

The strongest argument for AORT centers on Price/Book.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.3%.

Bear Case : AORT

The primary concerns for AORT are EPS Growth, Market Cap, Operating Margin.

Bear Case : NVS

The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.

Key Dynamics to Monitor

AORT profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.

AORT carries more volatility with a beta of 1.28 — expect wider price swings.

AORT is growing revenue faster at 9.2% — sustainability is the question.

NVS generates stronger free cash flow (4.8B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (48/100 vs 35/100), backed by strong 17.5% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Artivion Inc

HEALTHCARE · MEDICAL DEVICES · USA

Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?